-
Aug 16, 2024 | 
jdsupra.com | Alan Arville |Alexis Boaz |Christopher Smith
On July 31, the Centers for Medicare and Medicaid Services (“CMS”) published its mammoth proposed rule entitled “Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments” (“CY25 PFS Proposed Rule”).
-
Aug 16, 2024 | 
natlawreview.com | Alan Arville |Alexis Boaz |John Henson |Stefanie Marrone
Skip to main content August 16, 2024 Volume XIV, Number 229 Legal Analysis. Expertly Written. Quickly Found. Trending News United States | Keeping Families Together Form I-131F available Aug.
-
Apr 1, 2024 | 
jdsupra.com | Alexis Boaz |Helaine I. Fingold |Karen Mandelbaum
The Centers for Medicare & Medicaid Services (CMS) recently published the CMS Advancing Interoperability and Improving Prior Authorization Processes Final Rule (“PA Final Rule”) in the Federal Register. Effective April 8, 2024, with rolling implementation dates of certain provisions, the PA Final Rule imposes requirements on payers that will have wide-reaching impacts across other health care stakeholders—particularly providers and patients.
-
Mar 26, 2024 | 
natlawreview.com | Alexis Boaz
Skip to main content March 26, 2024 Volume XIV, Number 86 Legal Analysis. Expertly Written. Quickly Found.
-
Jan 1, 2024 | 
healthlawadvisor.com | Alan Arville |Alexis Boaz |Christopher Smith |James S. Tam
On July 31, the Centers for Medicare and Medicaid Services (“CMS”) published its mammoth proposed rule entitled “Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments” (“CY25 PFS Proposed Rule”).
-
Oct 27, 2023 | 
natlawreview.com | Alexis Boaz
Skip to main contentOctober 27, 2023Volume XIII, Number 300Legal Analysis. Expertly Written. Quickly Found.
-
Aug 14, 2023 | 
jdsupra.com | Alexis Boaz |Helaine I. Fingold
On August 3, 2023, the U.S. Department of Health & Human Services (“HHS”), the Department of Labor, and the Department of Treasury (collectively, the “Departments”) temporarily suspended the federal Independent Dispute Resolution (“IDR”) process immediately following the issuance of a decision by the U.S. District Court for the Eastern District of Texas (the “Court”) that vacated certain regulations and guidance the Departments issued to implement the No Surprises Act (“NSA”).
-
Aug 14, 2023 | 
natlawreview.com | Alexis Boaz
On August 3, 2023, the U.S. Department of Health & Human Services (“HHS”), the Department of Labor, and the Department of Treasury (collectively, the “Departments”) temporarily suspended the federal Independent Dispute Resolution (“IDR”) process immediately following the issuance of a decision by the U.S. District Court for the Eastern District of Texas (the “Court”) that vacated certain regulations and guidance the Departments issued to implement the No Surprises Act (“NSA”).
-
Aug 14, 2023 | 
lexblog.com | Alexis Boaz |Helaine I. Fingold
On August 3, 2023, the U.S. Department of Health & Human Services (“HHS”), the Department of Labor, and the Department of Treasury (collectively, the “Departments”) temporarily suspended the federal Independent Dispute Resolution (“IDR”) process immediately following the issuance of a decision by the U.S. District Court for the Eastern District of Texas (the “Court”) that vacated certain regulations and guidance the Departments issued to implement the No Surprises Act (“NSA”).
-
Mar 7, 2023 | 
natlawreview.com | Alexis Boaz
On February 9, 2023, the Centers for Medicare & Medicaid Services (“CMS”) issued a fact sheet and its initial guidance documents addressing the Medicare Prescription Drug Inflation Rebate Program for Medicare Parts B and D (the “Inflation Rebates”)—a critical component of the sweeping prescription drug pricing changes enacted through the Inflation Reduction Act of 2022 (the “IRA”).
